OrthoIndy channeling Walmart in comeback bid
The local orthopedic surgeons are presenting themselves as low-cost providers in an attempt to reverse growth restrictions imposed by Obamacare.
The local orthopedic surgeons are presenting themselves as low-cost providers in an attempt to reverse growth restrictions imposed by Obamacare.
By and large, Obamacare will leave in place the same major problems in the health care systems that existed before the law was passed—in both Indiana and across the nation.
Roche’s diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
Obamacare is destined to fail for one key reason: it will make health insurance cost more and buy less.
This is the first of three blog posts, each of which will make a compelling case for one of three distinct positions on Obamacare in Indiana: why it will succeed, why it will fail and why it will be a “non-event.”
Even as it tries narrow networks, health insurer is trying to offer more choice of doctors now, but push for lower provider payments later.
Franciscan St. Francis Health earned a $6.6 million bonus from the Medicare program for its success at keeping central Indiana patients out of the hospital and the emergency room. So the hospital system will expand its participation in so-called accountable care programs to all its Indiana territories.
Hospitals already operate like for-profit businesses, but now a financial pinch is making more hospitals join their ranks. Aggressive moves by St. Vincent’s parent organization are just the beginning.
As the Pence administration continues to negotiate with the feds, local hospitals say their recent cuts would not have been changed even if Indiana had expanded its Medicaid program.
Soon to change its name to Eskenazi Health, the county-owned hospital in Indianapolis is using a business model that tries to promote patients’ health, rather than merely treat their diseases.
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
Compensation in the most common physician specialties has been growing much faster than inflation for the past five years. Now, financially squeezed hospitals are set to reverse that trend.
With recent attention focused on hospital prices, WellPoint and its peers have been enjoying a nice break from their long-running status as Public Enemy No. 1 in the nation’s health care debate. They shouldn’t expect it to last.
A new recommendation from the Medicare Payment Advisory Commission, if enacted, would likely end one of the ways Indianapolis-area hospitals have generated healthy revenue from their recent spree of physician acquisitions.
To get control of health care spending, prominent health policy wonks are calling for new rules requiring hospitals and insurers to raise the ‘veil of secrecy’ they have thrown over their prices for decades.
Whenever a new report claims hospitals are charging too much, a stock set of defenses comes out. But hospitals are cutting prices and expenses as we speak, undermining those arguments.
In the first post on my new blog, The Dose, I explain why the recently released Medicare charge data are meaningless for everyone but uninsured patients.
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Rather than raising prices on private health insurers to make up for inadequate payments from the government, hospitals across the country have been raising prices just because they can, according to a new study.
Shares of Indianapolis-based WellPoint rose along with those of other medical insurers Tuesday morning after the U.S. government reversed a decision to cut a key Medicare payment rate, offering them an increase instead.